Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Eur J Neurosci. Author manuscript; available in PMC 2011 July 14.
Published in final edited form as:
PMCID: PMC2955837

Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies


Recently, several novel, potentially lethal, and treatment-responsive syndromes that affect hippocampal and cortical function have been shown to be associated with auto-antibodies against synaptic antigens, notably glutamate or GABA-B receptors. Patients with these auto-antibodies, sometimes associated with teratomas and other neoplasms, present with psychiatric symptoms, seizures, memory deficits, and decreased level of consciousness. These symptoms often improve dramatically after immunotherapy or tumor resection. Here we discuss studies of the cellular and synaptic effects of these antibodies in hippocampal neurons in vitro and preliminary work in rodent models. Our work suggests that patient antibodies lead to rapid and reversible removal of neurotransmitter receptors from synaptic sites, leading to changes in synaptic and circuit function that in turn are likely to lead to behavioral deficits. We also discuss several of the many questions raised by these and related disorders. Determining the mechanisms underlying these novel anti-neurotransmitter receptor encephalopathies will provide insights into the cellular and synaptic bases of the memory and cognitive deficits that are hallmarks of these disorders, and potentially suggest avenues for therapeutic intervention.

Keywords: synaptic plasticity, glutamate receptors, autoimmune, encephalitis, hippocampus

Many encephalitides once considered idiopathic are now thought to be immune mediated. One of these disorders predominantly affects structures of the limbic system, including medial temporal lobes, amygdala, hippocampus, and orbitofrontal cortex (Gultekin et al., 2000; Posner & Dalmau, 2000; Graus & Dalmau, 2007). As a result, patients develop short-term memory deficits, emotional and behavioral disturbances such as confusion, irritability, depression, and sleep disturbances, as well as seizures and sometimes dementia (Gultekin et al., 2000; Tüzün & Dalmau, 2007). For many years limbic encephalitis was invariably attributed to the paraneoplastic manifestation of cancers that express the target neuronal antigen, and the neurological deficits were considered refractory to treatments. These views have changed with the discovery of an expanding group of encephalitides that occur with or without cancer association, respond to immunotherapy, and range from focal limbic dysfunction to a multifocal or diffuse encephalopathy. In contrast to classical paraneoplastic encephalitides in which the target antigens are intracellular and appear to be mediated by cytotoxic T-cell mechanisms, the novel group of disorders associates with autoantigens that are on the cell or synaptic surface and appear to be directly mediated by antibodies.

The pathogenic role of antibodies can be established using several criteria in vitro and in vivo. First, if antigens are membrane proteins, antibodies should have access to and bind extracellular antigenic epitopes in living cells and/or tissues. Second, that antibodies recognize a particular antigen should be assessed by expressing the antigen in heterologous cells, assayed by immunostaining or immunoprecipitation followed by Western blot. Third, antibodies cause structural and/or functional alterations of the target antigen that can be established in vitro in dissociated neuron cultures as well as in vivo after antibody infusion. Adjuncts to these approaches would include using affinity purified antibody to recapitulate the effects of human CSF or serum, as well as demonstrating that CSF or serum depleted of the particular antibody has no structural or functional effects on cells. In the particular case of antibodies against neurotransmitter receptors or ion channels, receptor/channel function may well be acutely or chronically altered by antibody treatment, leading secondarily to changes in cellular and/or synaptic function. Fourth, the clinical syndrome should mirror some or all of the phenotypes of pharmacological or genetic manipulation of the antigen. Fifth, passive transfer of disease-specific antibodies to animals should recapitulate the effects of the antibodies on the antigen as well as the clinical features of the disorder. Sixth, cellular and synaptic alterations, and clinical symptoms, should improve as antibody titer is reduced. For some autoimmune diseases such as myasthenia gravis or Lambert-Eaton syndrome, all of these criteria have been met; however, for many, only a subset has been confirmed (Table 1).

Table 1
Immune mediated disorders of the synapse

Anti-neurotransmitter receptor limbic encephalitides resemble the autoimmune syndromes of the neuromuscular synapse (e.g., myasthenia gravis) in that they can also occur with or without tumor association and are likely antibody-mediated (Table 1; Rudnicki & Dalmau, 2000; Phillips, 2003; Tormoehlen & Pascuzzi, 2008; Meriggioli & Sanders, 2009b). However, in autoimmune synaptic encephalitis the autoantigen is located behind the blood-brain-barrier (BBB), requiring that the antibodies or cells producing antibodies cross this barrier in order to cause neurological dysfunction (Figure 1). In some disorders the patients' cerebrospinal fluid (CSF) show lymphocytic pleocytosis and intrathecal synthesis of antibodies suggesting that after initial systemic immune activation by a tumor or unknown causes, there is an expansion of the immune response within the nervous system (Dalmau & Rosenfeld, 2008). The role of the immune response in the neurological symptoms is further supported by the correlation between antibody titers and symptoms, and the frequent response of the disorders to immunotherapies, including plasmapheresis, IVIg, corticosteroids, cyclophosphamide, or rituximab, a monoclonal antibody that depletes B cells.

Figure 1
Mechanisms involved in the presence of antibodies in the central nervous system

The importance of these disorders is that they offer human models of brain-immune interactions in which the target antigens have critical roles in neuronal synaptic transmission and plasticity. Therefore, their study will improve our understanding of the effects of the antibodies at the cellular, synaptic and circuit levels, eventually impacting the clinical management of the patients. Here we describe the three most recently identified autoimmune synaptic encephalitides and the state of our understanding of the cellular and synaptic mechanisms, and discuss some of the many questions raised by these diseases.

Anti-NMDA receptor encephalitis

A new, severe, potentially lethal, and treatment-responsive disorder, anti-NMDA receptor encephalitis was reported within the last several years by Dalmau and colleagues (Dalmau et al., 2007; Sansing et al., 2007). Patients are usually young women, but also include men, without a past medical history of interest, who, often after prodromic symptoms of mild hyperthermia, headache, or a viral-like process, develop sudden behavioral and personality changes for which they are often seen by psychiatrists (Dalmau et al., 2007; Sansing et al., 2007). This clinical presentation is usually followed by seizures, decreased level of consciousness, abnormal movements (orofacial and limb dyskinesias, dystonia, choreoathetosis), autonomic instability (fluctuating blood pressure, cardiac rhythms, and temperature), and sometimes hypoventilation. MRI is frequently normal, but in about 40% of patients inflammation is transiently identified in hippocampus, cerebral or cerebellar cortex, and subcortical regions (Dalmau et al., 2008; Davies et al., 2010; Kataoka et al., 2008; Gable et al., 2009b; Kataoka et al., 2009; Niehusmann et al., 2009). Patients have serum and CSF antibodies that react with brain antigens predominantly expressed in the hippocampus (Dalmau et al., 2008). In two large cohorts comprising 181 patients, including young adults and children, neurologic improvement was correlated with a decrease in antibody titer (Dalmau et al., 2008; Florance et al., 2009). Overall, about 75% of the patients had dramatic or substantial recoveries despite the severity or long duration of symptoms; 19% had partial or limited improvement, and 6% died. Analyses of brain biopsies in 14 cases and autopsy of three patients showed microgliosis, occasional inflammatory B-cell and plasma cell infiltrates, and very rare T-cell infiltrates, in contrast to other paraneoplastic syndromes in which cytotoxic T-cell infiltrates are prominent (Stein-Wexler et al., 2005). In the autopsy studies the most prominent microglial activation localized in the hippocampus. Most patients with this disorder were previously categorized as “encephalitis of unknown etiology” (Iizuka et al., 2008; Gable et al., 2009a). It is likely that many patients died without a diagnosis or recovered with empiric treatment with immunotherapy. In fact, the little autopsy material that is available for analysis comes from cases diagnosed retrospectively using archived tissue, serum or CSF. The current mortality rate of anti-NMDA receptor encephalitis is ~3%, usually as a result of complications during the stage that patients require intensive care and ventilatory support (Dalmau et al., 2008; Florance et al., 2009; Gable et al., 2009).

When patient antibodies are used to stain rodent brain sections, immunoreactivity is observed in the neuropil of the hippocampus, with less staining in cortex, striatum and cerebellum (Dalmau et al., 2008). When used to stain live cultured hippocampal neurons, patient antibodies react with surface antigens localized to synapses. Additional studies, including immunoprecipitation followed by mass spectroscopy, led to the identification of the NR1 subunit of NMDA receptor as the target autoantigen. NMDA receptors are usually formed from heteromers of two NR1 and two NR2 subunits (Kendrick et al., 1996; Laube & Kiderlen, 1997). There are four NR2 subunits (NR2A-D), which have 50-70% sequence identity in the extracellular domain; NR1 is ubiquitously distributed in the brain (Monyer et al., 1994; Standaert et al., 1994; Waxman & Lynch, 2005). Domain swapping and other experiments showed that the epitope was located at the N-terminal extracellular domain of NR1 (Dalmau et al., 2008; (Gleichman et al., 2009). Since NR1 is ubiquitously expressed in brain as an obligate subunit of functional NMDA receptors (Monyer et al., 1994; Standaert et al., 1994; Waxman & Lynch, 2005), it remains unclear why patient NR1 antibodies preferentially label hippocampus rather than all brain regions. This binding pattern may reflect the relative high density of NMDA receptors in the hippocampus or a differential posttranslational modification of NR1 in different brain regions (Gleichman et al., 2009).

We have recently shown that patients' antibodies cause a selective, titer-dependent decrease of NMDA receptor surface density, synaptic localization, and currents in vitro, via antibody mediated capping and internalization (Figure 2; Hughes et al., 2010), while overall cellular structure and synaptic density were largely unchanged. Moreover, these effects were reversible: after 3 days of treatment with patients' CSF, followed by 4 days of treatment with control CSF, NMDA receptor cluster density and synaptic localization recovered to levels seen in control cultures. In addition, NMDA receptor density was dramatically reduced in the hippocampus of rats infused with patients' antibodies and in the hippocampus of autopsied patients (Hughes et al., 2010). These studies demonstrated that patients' NR1 antibodies reversibly alter the number and distribution of glutamate receptors in neurons, resulting in a decrease in glutamatergic synaptic function. The lack of neuronal death and the reversibility of the effects of antibodies on cultured neurons may explain, in part, the frequent recovery of patients with this disorder. It is unclear, however, whether the prolonged time of recovery (usually several months) represents persistence of the immune response in the brain, slow recovery of circuit dysfunction caused by the decrease of synaptic NMDA receptors, or both.

Figure 2
Mechanisms underlying cellular and synaptic effects of anti-NMDA receptor antibodies

Other autoimmune synaptic encephalitides

A goal of our ongoing work is to determine whether other syndromes may involve antibodies to other surface or synaptic antigens. Currently, ~90% of patients with limbic encephalitis of non-viral etiology that we have studied have well-defined immune responses against neuronal antigens (Bataller & Dalmau, 2004; Bataller et al., 2007; Graus et al., 2008). The importance of antibodies to cell surface or synaptic proteins was shown in a recent study in which these antibodies were found to be more prevalent than antibodies to intracellular antigens described in paraneoplastic disorders (54% versus 24%; Graus et al., 2008)). A study of 1570 patients with diffuse encephalitis by the California Encephalitis Project showed that in only 30% could a final diagnosis be established (viral, bacterial, prion, parasitic, fungal; Glaser et al., 2006). A pilot study examining a group of cases selected by subphenotype (“encephalitis, psychosis, and dyskinesias”) showed that 50% had NMDA receptor antibodies (Gable et al., 2009a). This suggests that other antibodies to currently unknown antigens may occur in the remaining cases.

In the last 2 years, a second form of immune mediated encephalitis in which patients' serum and CSF antibodies are directed against AMPA receptors was identified (Lai et al., 2009). Most patients develop a clinical picture of limbic encephalitis including confusion, agitation, seizures, and severe short-term memory deficits. Sometimes patients present with a rapidly progressive abnormal behavior that resembles acute psychosis. Patients are usually women older than 50 years, and 70% had an underlying tumor, usually lung or breast cancer or tumors of the thymus that express AMPA receptors. Immunotherapy and treatment of the tumor, if detected, usually results in neurological recovery. The neurological disorder has a tendency to relapse, and for these patients the outcome depends of how well each relapse is controlled.

Staining of live cultured hippocampal neurons with patients' serum or CSF showed that patient antibodies recognized cell surface antigens that were localized to synapses. Immunoprecipitation followed by mass spectrometry demonstrated that the target antigens were the GluR1 and/or GluR2 subunits of the AMPA receptors. AMPA receptors mediate most of the fast excitatory synaptic transmission in the brain (Shepherd & Huganir, 2007) and the majority are heterotetramers composed of GluR1, 2, 3 or 4 subunits that are expressed in a region-specific manner (Palmer et al., 2005). GluR1/2 and GluR2/3 levels are high in hippocampus and other limbic regions (Sprengel, 2006), similar to the distribution of immunostaining with patients' antibodies. Preliminary analyses suggest that the location of the epitope is the N-terminal extracellular domain of these AMPA receptor subunits (Gleichman et al., 2009). None of these patients' antibodies reacted with GluR3, a subunit identified as an autoantigen in some patients with Rasmussen's encephalitis (Rogers et al., 1994).

Treatment of rat hippocampal neurons with patients' antibodies resulted in a significant decrease in the synaptic localization of AMPA receptor clusters, without a decrease in overall synaptic density or NMDA receptor clusters (Lai et al., 2009). Moreover, these effects were reversible: after 3 days of treatment with patients' CSF containing GluR1/GluR2 antibodies, followed by 4 days of treatment with control CSF, AMPA receptor cluster density and synaptic localization recovered to levels seen in control cultures (Lai et al., 2009).

A third subtype of autoimmune encephalitis associated with antibodies against the γ-amino-butyric acid-B (GABAB) receptor was also recently identified (Lancaster et al., 2009). The median age of a cohort of 15 patients was 62 years (24-75); 8 were men. All presented with early and prominent seizures; other symptoms, as well as MRI and EEG findings, were consistent with predominant limbic dysfunction. Forty-seven percent of patients had small cell lung cancer (SCLC), and 40% showed propensity to autoimmunity. Cancer screening and demographic data indicate the disorder also occurs in patients without cancer. Neurological improvement occurred in 60% of the patients and was correlated with prompt immunotherapy and tumor control. Staining of live neurons showed that all patients serum and CSF had antibodies against a cell surface antigen. Immunoprecipitation and mass spectroscopy demonstrated that the autoantigen was the B1 subunit of the GABAB receptor, a metabotropic receptor that when disrupted causes seizures and memory dysfunction (Prosser et al., 2001; Schuler et al., 2001).

Three syndromes have been shown to be associated with antibodies against voltage-gated potassium channels (Kleopa et al., 2006). Neuromyotonia is a peripheral nervous system disorder characterized by muscle hyperactivity, while Morvan's syndrome, in addition to peripheral muscle hyperactivity, has autonomic and central nervous system manifestations, including insomnia, hallucinations, anxiety, delirium, and memory loss (Kleopa et al., 2006). The third, limbic encephalitis, consists only of central nervous system symptoms with no peripheral dysfunction (Kleopa et al., 2006).Similar to the encephalitides presented above, this type of limbic encephalitis can be paraneoplastic but also more frequently occurs in the absence of a tumor (Buckley et al., 2001; Vincent et al., 2004; Geschwind et al., 2008). Patients experience psychiatric and neurological symptoms including short-term memory loss, disorientation, memory loss, agitation, hallucinations, and seizures, as well as excessive secretions (Buckley et al., 2001; Thieben et al., 2004; Vincent et al., 2004; Geschwind et al., 2008). In addition, voltage gated potassium channel antibodies have also been reported in patients with isolated seizures and rapidly progressive dementia, sometimes suggesting a prion disease (Geschwind et al., 2008).

A number of other synaptic autoimmune disorders have been identified. These disorders affect neurological functions other than memory, behavior and cognition, and therefore are only briefly described here. Two patients with cerebellar ataxia were found to have antibodies against mGluR1 (Smitt et al., 2007). Autonomic neuropathy, a disorder affecting various autonomic nervous system functions, can associate with antibodies against ganglionic acetylcholine receptors (Vernino et al., 1998; Vernino et al., 2000). Patients with Miller-Fisher syndrome, a variant of Guillain-Barre causing extraocular paralysis, produce antibodies against ganglioside type GQ1b that cause a complement-mediated block of neuromuscular transmission (Plomp et al., 1995). Antibodies against glycine receptors have been reported in one patient with Progressive Encephalomyelitis, Rigidity, and Myoclonus (PERM), resulting in muscle spasms and rigidity, facial muscle weakness, and gaze palsies (Hutchinson et al., 2008). While these syndromes are of clinical interest, the underlying cellular mechanisms remain to be determined.

While in vitro approaches have been useful to establish the effects of antibodies to NMDA, AMPA, and GABAB1 receptors on neurons and in particular on synapses, in vivo models will be needed to establish the relationship between the effects of each antibody on synapse and circuit function, and the changes in behavior, memory and cognition that are hallmarks of these disorders. Below we discuss several of many outstanding questions that, when addressed, will provide new insights into the basic neuroscience of synaptic plasticity as well as the clinical understanding of autoimmune encephalitides.

Paraneoplastic and non-paraneoplastic mechanisms of autoimmune synaptic encephalitides

Anti-NMDA, -AMPA, and -GABAB1 receptor encephalitides are often paraneoplastic syndromes. In this setting the presence of a tumor that expresses these receptors likely contributes to breaking immune tolerance. However, other unknown immunological triggers may be involved, particularly in patients without tumor. A propensity toward autoimmunity is suggested by the frequent occurrence of other immune responses, and in the case of anti-NMDA receptor encephalitis, an apparent predominance in ethnic groups (African-American, Asian, Latinos; Gable et al., 2009a).

As in other autoimmune diseases, a number of mechanisms could potentially account for the immune response in the absence of a tumor. Cross reactivity of antibodies against different antigens can occur if the epitopes are sufficiently similar. Guillain-Barré syndrome is an autoimmune peripheral neuropathy affecting axons and myelin sheaths (Hahn, 1998; Hughes & Cornblath, 2005). The disorder is frequently preceded by an infection, often by Campylobacter jejuni (Rees et al., 1995; Alios, 1997; McCarthy & Giesecke, 2001). Patients' serum antibodies react with peripheral nerve gangliosides as well as lipooligosaccharide from Campylobacter jejuni (Oomes et al., 1995; Ang et al., 2004; Yuki et al., 2004). Other examples include Sydenham's chorea and systemic lupus erythematosus (SLE). Sydenham's chorea is characterized by abnormal movements, hypotonia, and neuropsychiatric symptoms, and characteristically occurs after an infection by group A streptococci (Marques-Dias et al., 1997; Kirvan et al., 2006a). Antibodies from these patients react with gangliosides expressed in the basal ganglia and cross-react with group A streptococcal N-acetyl-glucosamine (Bronze & Dale, 1993; Kirvan et al., 2003; Kirvan et al., 2006b). In SLE, patients with neuropsychiatric symptoms and sometimes asymptomatic family members harbor antibodies to double stranded DNA that also cross react with a single epitope present in the extracellular region of NR2A and NR2B of the NMDA receptor (DeGiorgio et al., 2001; Kowal et al., 2006a).

Given that most paraneoplastic disorders are triggered by small tumors at initial stages of the disease, it is possible that an immune response resulting in antibody synthesis decreases the size or eliminates the tumor by antibody binding and complement mediated cytotoxicity. Thus at the time of diagnosis, antibodies are present, but no tumor is detected. A better understanding of the events that trigger the immune response in anti-NMDA receptor encephalitis and other autoimmune encephalitides will be important in both treatment and prevention of these and other related disorders.

The source and brain access of autoantibodies to synaptic antigens

Two possible, not mutually exclusive, mechanisms that explain the presence of synaptic autoantibodies in the CNS include passive IgG crossing of the BBB, and intrathecal or cerebral synthesis of antibodies by plasma cells (see Figure 1).

The first possibility is that antibodies synthesized in the periphery cross a pathologically disrupted BBB, or through regions where the BBB is normally leaky (area postrema) or more susceptible to systemic changes (e.g., stress, high blood pressure). Several methods for experimentally increasing BBB permeability have been described in the literature, including focal ultrasound (Kinoshita et al., 2006), hypertonic solute (Neuwelt et al., 1988; Doolittle et al., 2000), and lipopolysaccharide (Xaio et al., 2001). More physiologically relevant models of BBB disruption include peripheral inflammation (Rabchevsky et al., 1999; Huber et al., 2001), acute stress (Esposito et al., 2002), and epinephrine (Huerta et al., 2006). Several studies have shown that peripherally administered antibodies can access the brain following these breaches in BBB integrity. Iodinated antibodies injected into rats were detected in the brain following osmotic opening of the BBB (Neuwelt et al., 1988). Kinoshita et al. showed that focal sonication caused BBB disruption allowing intravenously injected dopamine receptor antibodies to enter the brain and bind to antigen at sites of barrier breakdown (Kinoshita et al., 2006).

The second possibility is that antibodies are synthesized intrathecally. Most patients with anti-NMDA, -AMPA or -GABAB receptor encephalitis have an increased ratio of CSF to serum IgG concentration, indicating intrathecal synthesis of antibodies. Moreover, protein electrophoretic analyses of the CSF of these patients often demonstrates multiple distinct bands of IgG that are absent in serum (oligoclonal bands), suggesting the presence of plasma cell clones within the thecal space that secrete distinct immunoglobulins (Dalmau et al., 2008). Extensive clinical and immunological data from patients with anti-NMDA receptor encephalitis suggest a model in which both passive crossing and intrathecal synthesis of antibodies occur. Given that most patients present with prodromal symptoms (hyperthermia, undetermined viral-like infection) it is likely that the BBB is transiently disrupted. This is supported by studies showing transient FLAIR MRI changes involving cortical or subcortical regions. Additionally, after systemic immune activation by a NMDA receptor-expressing tumor or other unknown factors, memory B-cells that are able to cross a normal BBB will undergo re-stimulation, antigen-driven affinity maturation, clonal expansion, and differentiation into NMDA receptor antibody-secreting plasma cells. This mechanism, that has been involved in other autoimmune diseases such as multiple sclerosis (Hauser et al., 2008), would explain the detection of intrathecal synthesis of antibodies in most patients with anti-NMDA receptor encephalitis. Moreover, the occurrence of both passive BBB transfer and intrathecal synthesis of antibodies explains the increasing symptom refractoriness to predominant serum IgG depleting strategies (IVIg, plasma exchange) during the course of the disease. Patients that do not respond to these treatments often improve with cyclophosphamide and rituximab that are more effective in reducing intrathecal synthesis of antibodies. A better understanding of the site and dynamics of antibody synthesis during the course of these disorders is crucial for improving treatment methods and delivery.

Mechanisms underlying antibody pathogenic effects on the target receptors

Several mechanisms may account for the pathogenicity of autoantibodies in these disorders. These include agonizing or antagonizing the receptor, causing receptor internalization and degradation resulting in diminished receptor function, or stimulating complement-mediated neuronal damage. Each of these effects has been demonstrated in autoimmune diseases of the nervous system, and in some, more than one of these effects contributes to the disease process.

The first possibility is that patient anti-receptor antibodies agonize or antagonize the receptor. NR2 antibodies from patients with SLE cause neuronal death when injected into mouse brain; this effect is attenuated by treatment with the NMDA receptor blocker, MK-801, suggesting the antibodies mediate cell death by enhancing channel activation (DeGiorgio et al., 2001). Conversely, application of nicotinic acetylcholine receptor (nAChRs) antibodies from myasthenia gravis patients to outside-out patches of mouse myotubes caused an acute block of AChR currents that became irreversible with time (Jahn et al., 2000a). With respect to patient NMDA and AMPA receptor antibodies, we have not yet found clear evidence supporting direct agonism or antagonism of receptor function. However, the fact that the epitope for both NMDA receptor and AMPA receptor antibodies is in the N-terminus raises the possibility that autoantibodies could have direct functional effects. The ligand binding domain for both channels is also in the N-terminus, and conformational changes are thought to couple ligand binding to channel opening (Armstrong & Gouaux, 2000; Sobolevsky et al., 2009). Therefore, patient antibodies could sterically hinder ligand binding or enhance its effects. In addition, N-terminal binding sites for channel modulators such as zinc and polyamines may be obscured by patients' antibodies (Rassendren et al., 1990; Herin & Aizenman, 2004; Paoletti & Neyton, 2007). Whole cell recording experiments during acute application of antibodies will allow this issue to be resolved.

The second possibility is that patient anti-receptor antibodies cause receptor internalization and degradation, resulting in diminished receptor function. AChR antibodies from patients with myasthenia gravis cause a loss of surface AChRs by cross-linking and internalization (Drachman et al., 1978). Cross-linking and internalization of voltage gated calcium channels by autoantibodies has also been shown to occur in patients with Lambert-Eaton syndrome (Nagel et al., 1988a; Peers et al., 1993a). In anti-NMDA receptor encephalitis, we have shown that the loss of surface NMDA receptors is the result of antibody mediated cross-linking and internalization (see Figure 2). Treatment of cultured neurons with monovalent Fab fragments generated from patients' antibodies did not induce receptor internalization, but subsequent crosslinking with anti-Fab antibodies recapitulated the decrease caused by intact patient NMDA receptor antibodies (Hughes et al., 2010). These data demonstrate that patients' antibodies produce both structural and functional changes at the synapse. Determining the range of effects of patients' antibodies (short-term, long-term, and dynamics of recovery) will provide insight into the synaptic basis of the memory and behavioral changes seen in these patients, and help to establish the roles of NMDA receptor signaling in human behavior and cognition.

The third possibility is that patient anti-receptor antibodies cause complement-mediated neuronal damage or death. Muscle biopsies from patients with myasthenia gravis have revealed extensive deposits of components of the complement cascade (Engel et al., 1977; Sahashi et al., 1980). Autopsy and in vitro studies have also linked complement activation with Rasmussen's encephalitis and neuromyelitis optica, the later characterized by antibodies to aquaporin-4 (Whitney et al., 1999; Lucchinetti et al., 2002; Waters et al., 2008). IgG1 and IgG3, subclasses of IgG capable of activating complement, are the main IgG types of NMDA and AMPA receptor antibodies. In anti-NMDA receptor encephalitis, we have not found evidence of deposits of complement in autopsies of patients. In light of the substantial recoveries made by many of these patients, extensive neuronal damage due to complement activation seems unlikely. Furthermore, it is unclear whether the elements of the complement cascade that are present in the central nervous system are sufficient to induce complement-mediated lysis. Further studies are needed to determine the degree of involvement of complement mediated mechanisms in the brain and tumor of patients with synaptic autoimmune encephalitis.

Homeostatic compensatory changes in response to antibody-mediated decrease of receptor levels

Compensatory mechanisms at the cellular and synaptic level have been shown to occur in autoimmune disorders of the nervous system in humans and in experimental model systems. Studies from mouse models of myasthenia gravis and patients' tissue have shown an enhanced rate of synthesis of AChRs and increased expression levels of the α, β, δ, and ε subunits of the AChR, as well as increased acetylcholine release upon stimulation (Wilson et al., 1983; Guyon et al., 1994; Plomp et al., 1995; Guyon et al., 1998). Purkinje cells treated with IgG from patients with Lambert-Eaton syndrome show a loss of P/Q-type voltage gated calcium channel currents and a concomitant increase in R-type currents (Pinto et al., 1998). Deletion of the α-1a subunit of the P/Q-type channel in mice causes age related ataxia and muscle weakness and results in enhanced L- and N-type calcium channel currents in Purkinje cells (Jun et al., 1999).

These observations raise the possibility that homeostatic mechanisms occur in anti-NMDA receptor and anti-AMPA receptor encephalitis, though this remains to be demonstrated. Support for this idea comes from the changes in synaptic strength observed after pharmacological blockade of glutamate receptors. Several studies have shown that, after 48 hours of NMDA or AMPA receptor blockade, mEPSC amplitude is enhanced (Turrigiano et al., 1998; Sutton et al., 2006).

Effects of maternal antibodies on fetal development and subsequent behavior

While the symptoms of anti-NMDA receptor encephalitis are largely similar between children and adults, children tend to have less severe autonomic problems and increased speech dysfunction (Florance et al., 2009; Lebas et al., 2009). These differences, along with a subset of patients who were diagnosed during pregnancy, raise questions about the effects of anti-receptor antibodies on the developing brain, and the long-term consequences of fetal or pediatric exposure to the antibodies.

Several other autoimmune diseases are associated with abnormalities in offspring. Children born to mothers with SLE, especially male children, have higher rates of developmental and learning disabilities than children born to unaffected mothers (McAllister et al., 1997; Ross et al., 2003). In mice, in utero exposure to antibodies from SLE patient serum results in morphological and behavioral abnormalities in offspring (Lee et al., 2009). Maternal myasthenia gravis is often associated with arthrogryposis multiplex congenita, a condition caused by lack of fetal movements that is associated with joint contractures and muscle weakness in offspring (Polizzi et al., 2000). Interestingly, asymptomatic women who have children with this condition may harbor anti-AChR antibodies. Serum from these women contains antibodies only to a fetal subunit of the AChR, and is therefore specifically harmful to the fetus rather than the mother (Vincent et al., 1995; Riemersma et al., 1996). These studies highlight the devastating effects maternal autoantibodies can have on fetal development.

Studies of mothers of autistic children also raise the possibility that maternal antibodies may impact fetal development. Several studies of these women suggested that they harbor anti-neuronal antibodies in their serum, although the antigen(s) is unknown. For example, serum from a woman with an autistic child and a child with a severe language disorder contained antibodies that bound rodent neurons and caused behavioral and motor abnormalities in mice exposed to the serum as embryos (Dalton et al., 2003). In addition, serum from mothers with autistic children caused hyperactivity and stereotypic behavior in rhesus monkeys exposed prenatally to the serum (Martin et al., 2008). These results show that asymptomatic women may have circulating neuronal antibodies that have access to the fetal brain and may affect brain development.

Two women that developed anti-NMDA receptor encephalitis at 14 and 17 week of pregnancy, when the specific transplacental transfer of IgG1 and IgG3 is not yet fully developed, delivered apparently normal newborns. Studies performed in one of the babies showed a lack of antibodies in serum and CSF (Kumar et al., 2010). However, given the importance of synaptic activity, in particular glutamatergic and GABAergic transmission during neural circuit development, in utero exposure to antibodies from patients with anti-NMDA receptor encephalitis, or other autoimmune encephalitides, may potentially affect normal fetal brain development resulting in neurological and behavioral disturbances in offspring. Thus establishing a mechanistic link between anti-receptor antibodies, access to the developing brain, effects on synapses and circuits and ultimately behavior, assayed across the lifespan, will be important for resolving these issues in a broad spectrum of disorders.

Relating the effects of synaptic receptor antibodies to neurological symptoms

Glutamate binding to NMDA receptor and AMPA receptor is crucial for synaptic transmission and plasticity. Pharmacological blockade or genetic reduction of NMDA receptor or AMPA receptors has been shown to alter measures of learning and memory and other behaviors in animal models (Nishikawa et al., 1991; Mohn et al., 1999; Kapur & Seeman, 2002; Krystal et al., 2002b; Nabeshima et al., 2006; Large, 2007; Schmitt et al., 2007; Labrie et al., 2008). The balance between excitatory and inhibitory synaptic inputs is also altered, and this has been shown to affect circuit function and behavior (Prange et al., 2004; Hensch & Fagiolini, 2005; Levinson & El-Husseini, 2005; Murphy et al., 2005; Epsztein et al., 2006; Fritschy, 2008; Kehrer et al., 2008). In addition, NMDA (Olney et al., 1999; Coyle et al., 2003; Coyle & Tsai, 2004; Kapoor et al., 2006; Lindsley et al., 2006; Stahl, 2007b; a; Shim et al., 2008) and/or AMPA (Noga & Wang, 2002; Makino et al., 2003; Magri et al., 2006; Wiedholz et al., 2008; Zavitsanou et al., 2008) receptor hypofunction has been proposed to be part of the pathophysiological mechanisms underlying schizophrenia.

It's interesting to consider why patients with anti-NMDA receptor antibodies develop a complex syndrome that includes psychosis, learning and memory dysfunction, abnormal movements, autonomic instability and frequent hypoventilation, while those with AMPA receptor antibodies preferentially develop psychiatric and amnestic symptoms. Studies using genetic deletion of NMDA receptor or AMPA receptor subunits in mouse models provide some insight into this issue. While NR1 knockout mice die shortly after birth due hypoventilation (Li et al., 1994), mice with spatially restricted NR1 deletion can survive into adulthood (Nakazawa et al., 2004). CA1-specific NR1 knockouts have impaired spatial and temporal memory and a loss of CA1 LTP (Tsien et al., 1996). Mice with an inducible, reversible knockout of NR1 in forebrain show impairment in the maintenance of long-term memory if NR1 expression is turned off during the memory storage phase. In addition to memory deficits, targeted manipulation of NR1 expression can result in schizophrenia-like symptoms. Hypomorphic expression of NR1 leads to increased stereotypic behavior and decreased sociability, while early postnatal loss of NR1 in a subset of cortical and hippocampal interneurons results in decreased pre-pulse inhibition and increased social isolation-induced anxiety (Mohn et al., 1999; Belforte et al., 2010). Moreover, subanesthetic doses of NMDA receptor blockers such as phencyclidine and ketamine are psychotomimetic, and they recapitulate many of the positive and negative signs of schizophrenia in humans and rodents as well as repetitive orofacial movements, autonomic instability and seizures. (Luby et al., 1962; Krystal et al., 1994; Lahti, 2001; Krystal et al., 2002a) The remarkable similarity between these phenotypes, the effect of patients' antibodies resulting in a dramatic decrease of synaptic NMDA receptor clusters and function, and the reduced levels of NMDA receptors in autopsied patients, support an antibody-mediated pathogenesis of anti-NMDA receptor encephalitis, and strengthen the NMDA receptor hypofunction hypothesis of schizophrenia (Belforte et al., 2010).

The consequences of loss of AMPA receptor expression have also been studied in mouse models. Spatial learning and memory are largely unaffected in GluR1 knockout mice despite the fact that LTP is reduced in CA1 and CA3 (Zamanillo et al., 1999) and working memory is diminished (Reisel et al., 2002; Sanderson et al., 2007). GluR2 knockout mice show reduced exploration and impaired motor coordination. In these animals, AMPA receptor mediated synaptic transmission is reduced, but LTP is enhanced (Jia et al., 1996a; Gerlai et al., 1998). GluR2 knockout mice also have increased cell death (Feldmeyer et al., 1999; Oguro et al., 1999), possibly due to excitotoxicity related to increased, compensatory insertion of GluR1 homomeric AMPA receptors. While AMPA receptor subunit knockout mice have not provided a satisfying explanation for the role of AMPA receptors in synaptic plasticity related to learning and memory, the fact that patients with AMPA receptor antibodies have short-term learning and memory deficits argues that further studies at the circuit and behavioral levels are warranted.

GABAB1 receptor knockout mice display a variety of neurological and behavioral abnormalities, including spontaneous seizures, enhanced anxiety, hyperactivity, hyperalgesia, and impaired memory (Schuler et al., 2001; Prosser et al., 2001), suggesting dysfunction of the limbic system. Consistent with these experimental data, patients with anti-GABAB1 receptor antibodies present with an encephalitis that associates with early and prominent seizures, confusion, agitation, behavioral problems and severe short-term memory deficit along with MRI abnormalities predominantly involving the hippocampi. Interestingly, both GABAB1 receptor knock out mice and mice treated with a GABAB1 receptor antagonist, CGP56433A, exhibit antidepressant-like behavior in a forced swim test and a learned helplessness paradigm (Mombereau et al., 2004; Nakagawa et al., 1999), suggesting that GABA signaling may have disparate effects on different aspects of mood such as depression and anxiety. Combined with animal studies, these patients can provide rich insight into the role of GABAB1 receptor signaling in memory, behavior, and cognition.


We have begun to obtain a better cellular- and synaptic-level understanding of a new and remarkable group of immune-mediated behavioral and memory disorders. On the clinical side, we would like to know the frequency of these antibodies in patients with milder or form frustes of the syndromes (e.g., predominant psychosis, isolated refractory seizures), and whether the effects of antibodies on glutamate and GABA receptors, and synapses, vary according to different subgroups of patients, improving the diagnostic and treatment strategies. It is likely that the effects of antibodies on children (or antibody effects on immature hippocampal synapses) are different from those on adults (or on mature hippocampal synapses), and this may account for some of the behavioral differences between adults and children. Another critical question is the optimal type of immunotherapy at different stages of the disease, and the duration of treatment. In current clinical practice, most patients receive intravenous immunoglobulins, plasma exchange, and corticosteroids as the first line of therapy. When these fail, Rituximab (a B-cell depleting monoclonal antibody) and cyclophosphamide are increasingly being used in an attempt to modify the levels of antibodies behind the BBB. However, it is unclear whether or how these treatments modify the effects of antibodies on synapses.

On the basic neuroscience side, a major goal will be to develop and test rodent models in a battery of behavioral tests designed to assay hippocampal, amygdala, cortical and cerebellar function in each disorder. In this way, we can begin to relate the cellular, synaptic, and circuit effects of patients' antibodies to behavioral deficits in learning, memory, and other cognitive and motor manifestations.


We thank Dr. Myrna Rosenfeld and members of the Balice-Gordon and Dalmau labs for comments this manuscript, and Mrs. Marion Scott for technical assistance. This work was supported by grants from the NIH (CA89054 and CA107192 to J.D.), an NIH Research Challenge Grant (NS068204 to R.B.-G. and J.D.) and a McKnight Neuroscience of Brain Disorders Award to R.B.-G. and J.D.


  • Alios B. Association between campylobacter infection and Guillain-Barré syndrome. The Journal of Infectious Diseases. 1997;176:S125–S128. [PubMed]
  • Ang CW, Jacobs BC, Laman JD. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol. 2004;25:61–66. [PubMed]
  • Armstrong N, Gouaux E. Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron. 2000;28:165–181. [PubMed]
  • Bataller L, Dalmau JO. Paraneoplastic disorders of the central nervous system: update on diagnostic criteria and treatment. Semin Neurol. 2004;24:461–471. [PubMed]
  • Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry. 2007;78:381–385. [PMC free article] [PubMed]
  • Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, Quinlan EM, Nakazawa K. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nature neuroscience. 2010;13:76–83. [PMC free article] [PubMed]
  • Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, Valdez CR, Escalante A, del Rincon I, Gronseth G, Rhine CB, Padilla P, McGlasson D. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology. 2002;58:1214–1220. [PubMed]
  • Bronze MS, Dale JB. Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. J Immunol. 1993;151:2820–2828. [PubMed]
  • Buckley C, Oger J, Clover L, Tüzün E, Carpenter K, Jackson M, Vincent A. Potassium channel antibodies in two patients with reversible limbic encephalitis. Annals of Neurology. 2001;50:73–78. [PubMed]
  • Coyle JT, Tsai G. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol. 2004;59:491–515. [PubMed]
  • Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci. 2003;1003:318–327. [PubMed]
  • Cui Z, Wang H, Tan Y, Zaia KA, Zhang S, Tsien JZ. Inducible and reversible NR1 knockout reveals crucial role of the NMDA receptor in preserving remote memories in the brain. Neuron. 2004;41:781–793. [PubMed]
  • Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–1098. [PMC free article] [PubMed]
  • Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7:327–340. [PMC free article] [PubMed]
  • Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25–36. [PMC free article] [PubMed]
  • Dalton P, Deacon R, Blamire A, Pike M, McKinlay I, Stein J, Styles P, Vincent A. Maternal neuronal antibodies associated with autism and a language disorder. Ann Neurol. 2003;53:533–537. [PubMed]
  • Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. The New England Journal of Medicine. 1977;297:1134–1140. [PubMed]
  • Davies G, Irani SR, Coltart C, Ingle G, Amin Y, Taylor C, Radcliffe J, Hirsch NP, Howard RS, Vincent A, Kullmann DM. Anti-N-methyl-D-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit. Critical Care Medicine. 2010;38:679–682. [PubMed]
  • DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med. 2001;7:1189–1193. [PubMed]
  • Doolittle N, Miner M, Hall W, Siegal T, Hanson E, Osztie E, McAllister L, Bubalo J, Kraemer D, Fortin D, Nixon R, Muldoon L, Neuwelt E. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer. 2000;88:637–647. [PubMed]
  • Drachman DB, Angus CW, Adams RN, Michelson JD, Hoffman GJ. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med. 1978;298:1116–1122. [PubMed]
  • Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc. 1977;52:267–280. [PubMed]
  • Epsztein J, Milh M, Bihi RI, Jorquera I, Ben-Ari Y, Represa A, Crepel V. Ongoing epileptiform activity in the post-ischemic hippocampus is associated with a permanent shift of the excitatory-inhibitory synaptic balance in CA3 pyramidal neurons. J Neurosci. 2006;26:7082–7092. [PubMed]
  • Esposito P, Chandler N, Kandere K, Basu S, Jacobson S, Connolly R, Tutor D, Theoharides TC. Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther. 2002;303:1061–1066. [PubMed]
  • Feldmeyer D, Kask K, Brusa R, Kornau HC, Kolhekar R, Rozov A, Burnashev N, Jensen V, Hvalby O, Sprengel R, Seeburg PH. Neurological dysfunctions in mice expressing different levels of the Q/R site-unedited AMPAR subunit GluR-B. Nat Neurosci. 1999;2:57–64. [PubMed]
  • Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, Campen CJ, Moss H, Peter N, Gleichman AJ, Glaser CA, Lynch DR, Rosenfeld MR, Dalmau J. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66:11–18. [PMC free article] [PubMed]
  • Fritschy JM. Epilepsy, E/I Balance and GABA(A) Receptor Plasticity. Front Mol Neurosci. 2008;1:5. [PMC free article] [PubMed]
  • Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proceedings of the National Academy of Sciences of the United States of America. 1983;80:7636–7640. [PubMed]
  • Gable MS, Gavali S, Radner A, Tilley DH, Lee B, Dyner L, Collins A, Dengel A, Dalmau J, Glaser CA. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis 2009a [PMC free article] [PubMed]
  • Gable MS, Gavali S, Radner A, Tilley DH, Lee B, Dyner L, Collins A, Dengel A, Dalmau J, Glaser CA. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology. 2009b;28:1421–1429. [PMC free article] [PubMed]
  • Gerlai R, Henderson JT, Roder JC, Jia Z. Multiple behavioral anomalies in GluR2 mutant mice exhibiting enhanced LTP. Behavioural Brain Research. 1998;95:37–45. [PubMed]
  • Geschwind MD, Tan KM, Lennon VA, Barajas RF, Haman A, Klein CJ, Josephson SA, Pittock SJ. Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Archives of Neurology. 2008;65:1341–1346. [PMC free article] [PubMed]
  • Glaser CA, Honarmand S, Anderson LJ, Schnurr DP, Forghani B, Cossen CK, Schuster FL, Christie LJ, Tureen JH. Beyond viruses: clinical profiles and etiologies associated with encephalitis. Clin Infect Dis. 2006;43:1565–1577. [PubMed]
  • Gleichman A, Lai M, Zhou L, Hughes E, Peng X, Balice-Gordon R, Dalmau J, Lynch D. 2009 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience; 2009. Antigenicity of glutamate receptors. Online.
  • Graus F, Dalmau J. Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol. 2007;20:732–737. [PubMed]
  • Graus F, Saiz A, Lai M, Bruna J, Lopez F, Sabater L, Blanco Y, Rey MJ, Ribalta T, Dalmau J. Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology. 2008;71:930–936. [PMC free article] [PubMed]
  • Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123(Pt 7):1481–1494. [PubMed]
  • Guyon T, Levasseur P, Truffault F, Cottin C, Gaud C, Berrih-Aknin S. Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis. Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction. J Clin Invest. 1994;94:16–24. [PMC free article] [PubMed]
  • Guyon T, Wakkach A, Poea S, Mouly V, Klingel-Schmitt I, Levasseur P, Beeson D, Asher O, Tzartos S, Berrih-Aknin S. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss. J Clin Invest. 1998;102:249–263. [PMC free article] [PubMed]
  • Hahn AF. Guillain-Barré syndrome. Lancet. 1998;352:635–641. [PubMed]
  • Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–688. [PubMed]
  • Hensch TK, Fagiolini M. Excitatory-inhibitory balance and critical period plasticity in developing visual cortex. Prog Brain Res. 2005;147:115–124. [PubMed]
  • Herin GA, Aizenman E. Amino terminal domain regulation of NMDA receptor function. European Journal of Pharmacology. 2004;500:101–111. [PubMed]
  • Huber JD, Witt KA, Hom S, Egleton RD, Mark KS, Davis TP. Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol. 2001;280:H1241–1248. [PubMed]
  • Huerta PT, Kowal C, Degiorgio LA, Volpe BT, Diamond B. Immunity and behavior: antibodies alter emotion. Proc Natl Acad Sci USA. 2006;103:678–683. [PubMed]
  • Hughes E, Peng X, Gleichman A, Lai M, Zhou L, Tsou R, Parsons T, Lynch D, Dalmau J, Balice-Gordon R. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neuroscience. 2010 in the press. [PMC free article] [PubMed]
  • Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366:1653–1666. [PubMed]
  • Hutchinson M, Waters P, McHugh J, Gorman G, O'Riordan S, Connolly S, Hager H, Yu P, Becker CM, Vincent A. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology. 2008;71:1291–1292. [PubMed]
  • Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, Iigaya M, Suzuki K, Lynch DR, Suzuki N, Hata T, Dalmau J. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology. 2008;70:504–511. [PMC free article] [PubMed]
  • Jahn K, Franke C, Bufler J. Mechanism of block of nicotinic acetylcholine receptor channels by purified IgG from seropositive patients with myasthenia gravis. Neurology. 2000a;54:474–479. [PubMed]
  • Jahn K, Franke C, Bufler J. Mechanism of block of nicotinic acetylcholine receptor channels by purified IgG from seropositive patients with myasthenia gravis. Neurology. 2000b;54:474–479. [PubMed]
  • Jia Z, Agopyan N, Miu P, Xiong Z, Henderson J, Gerlai R, Taverna FA, Velumian A, MacDonald J, Carlen P, Abramow-Newerly W, Roder J. Enhanced LTP in mice deficient in the AMPA receptor GluR2. 1996a;17:945–956. [PubMed]
  • Jun K, Piedras-Rentería ES, Smith SM, Wheeler DB, Lee SB, Lee TG, Chin H, Adams ME, Scheller RH, Tsien RW, Shin HS. Ablation of P/Q-type Ca(2+) channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the alpha(1A)-subunit. Proc Natl Acad Sci USA. 1999;96:15245–15250. [PubMed]
  • Kapoor R, Lim KS, Cheng A, Garrick T, Kapoor V. Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1) Brain Res. 2006;1106:205–210. [PubMed]
  • Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2) receptors-implications for models of schizophrenia. Mol Psychiatry. 2002;7:837–844. [PubMed]
  • Kataoka H, Dalmau J, Taoka T, Ueno S. Reduced N-acetylaspartate in the basal ganglia of a patient with anti-NMDA receptor encephalitis. Movement Disorders: Official Journal of the Movement Disorder Society. 2009;24:784–786. [PubMed]
  • Kataoka H, Dalmau J, Ueno S. Paraneoplastic encephalitis associated with ovarian teratoma and N-methyl-D-aspartate receptor antibodies. European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies. 2008;15:e5-6–e5-6. [PubMed]
  • Kehrer C, Maziashvili N, Dugladze T, Gloveli T. Altered Excitatory-Inhibitory Balance in the NMDA-Hypofunction Model of Schizophrenia. Front Mol Neurosci. 2008;1:6. [PMC free article] [PubMed]
  • Kendrick SJ, Lynch DR, Pritchett DB. Characterization of glutamate binding sites in receptors assembled from transfected NMDA receptor subunits. J Neurochem. 1996;67:608–616. [PubMed]
  • Kim YI. Passive transfer of the Lambert-Eaton myasthenic syndrome: Neuromuscular transmission in mice injected with plasma. Muscle & Nerve. 1985;8:162–172. [PubMed]
  • Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun. 2006;340:1085–1090. [PubMed]
  • Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nature Medicine. 2003;9:914–920. [PubMed]
  • Kirvan CA, Swedo SE, Kurahara D, Cunningham MW. Streptococcal mimicry and antibody-mediated cell signaling in the pathogenesis of Sydenham's chorea. Autoimmunity. 2006a;39:21–29. [PubMed]
  • Kirvan CA, Swedo SE, Snider LA, Cunningham MW. Antibody-mediated neuronal cell signaling in behavior and movement disorders. J Neuroimmunol. 2006b;179:173–179. [PubMed]
  • Kleopa KA, Elman LB, Lang B, Vincent A, Scherer SS. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain: A Journal of Neurology. 2006;129:1570–1584. [PubMed]
  • Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, Diamond B. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci USA. 2006a;103:19854–19859. [PubMed]
  • Kowal C, DeGiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, Diamond B. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proceedings of the National Academy of Sciences. 2006b;103:19854–19859. [PubMed]
  • Krystal JH, Anand A, Moghaddam B. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry. 2002a;59:663–664. [PubMed]
  • Krystal JH, Anand A, Moghaddam B. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry. 2002b;59:663–664. [PubMed]
  • Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Jr, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199–214. [PubMed]
  • Kumar M, Jain A, Dechant W, Saito T, Rafael T, Aizawa H, Dysart K, Katayama T, Ito Y, Araki N, Abe T, Balice-Gordon R, Dalmau J. Anti-NMDA receptor encephalitis during pregnancy. Arch Neurol. 2010 in the press. [PubMed]
  • Labrie V, Lipina T, Roder JC. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2008;200:217–230. [PubMed]
  • Lahti A. Effects of Ketamine in Normal and Schizophrenic Volunteers. Neuropsychopharmacology. 2001;25:455–467. [PubMed]
  • Lai M, Hughes E, Peng X, Zhou L, Gleichman A, Shu H, Mata S, Kremens D, Vitaliani R, Geschwind M, Bataller L, Kalb R, Davis R, Graus F, Lynch D, Balice-Gordon R, Dalmau J. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65:424–434. [PMC free article] [PubMed]
  • Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MB, Grisold W, Kimura A, Ohta K, Iizuka T, Guzman M, Graus F, Moss SJ, Balice-Gordon R, Dalmau J. Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. The Lancet Neurology. 2009;9:67–76. [PMC free article] [PubMed]
  • Lang B, Newsom-Davis J, Prior C, Wray D. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. The Journal of Physiology. 1983;344:335–345. [PubMed]
  • Lang B, Vincent A. Autoimmune disorders of the neuromuscular junction. Current Opinion in Pharmacology. 2009;9:336–340. [PubMed]
  • Large CH. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol. 2007;21:283–301. [PubMed]
  • Laube U, Kiderlen AF. Detection of Pneumocystis carinii with DNA-binding bisBenzimide 33258 Hoechst. J Eukaryot Microbiol. 1997;44:35S. [PubMed]
  • Lebas A, Husson B, Didelot A, Honnorat J, Tardieu M. Expanding spectrum of encephalitis with NMDA receptor antibodies in young children. J Child Neurol. 2009 epub ahead of print. [PubMed]
  • Lee JY, Huerta PT, Zhang J, Kowal C, Bertini E, Volpe BT, Diamond B. Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat Med. 2009;15:91–96. [PMC free article] [PubMed]
  • Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A. IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain: A Journal of Neurology. 2008;131:1940–1952. [PubMed]
  • Lennon VA, McCormick DJ, Lambert EH, Griesmann GE, Atassi MZ. Region of peptide 125-147 of acetylcholine receptor alpha subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies. Proceedings of the National Academy of Sciences of the United States of America. 1985;82:8805–8809. [PubMed]
  • Levinson JN, El-Husseini A. New players tip the scales in the balance between excitatory and inhibitory synapses. Mol Pain. 2005;1:12. [PMC free article] [PubMed]
  • Leys K, Lang B, Vincent A, Newsom-Davis J. Calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome. Lancet. 1989;2:1107–1107. [PubMed]
  • Li Y, Erzurumlu RS, Chen C, Jhaveri S, Tonegawa S. Whisker-related neuronal patterns fail to develop in the trigeminal brainstem nuclei of NMDAR1 knockout mice. Cell. 1994;76:427–437. [PubMed]
  • Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL, Jr, Sur C, Kinney GG. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Top Med Chem. 2006;6:771–785. [PubMed]
  • Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF. Model Psychoses and Schizophrenia. Am J Psychiatry. 1962;119:61–67. [PubMed]
  • Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125:1450–1461. [PubMed]
  • Magri C, Gardella R, Barlati SD, Podavini D, Iatropoulos P, Bonomi S, Valsecchi P, Sacchetti E, Barlati S. Glutamate AMPA receptor subunit 1 gene (GRIA1) and DSM-IV-TR schizophrenia: a pilot case-control association study in an Italian sample. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:287–293. [PubMed]
  • Makino C, Fujii Y, Kikuta R, Hirata N, Tani A, Shibata A, Ninomiya H, Tashiro N, Shibata H, Fukumaki Y. Positive association of the AMPA receptor subunit GluR4 gene (GRIA4) haplotype with schizophrenia: linkage disequilibrium mapping using SNPs evenly distributed across the gene region. Am J Med Genet B Neuropsychiatr Genet. 2003;116B:17–22. [PubMed]
  • Marques-Dias MJ, Mercadante MT, Tucker D, Lombroso P. Sydenham's chorea. Psychiatr Clin North Am. 1997;20:809–820. [PubMed]
  • Martin LA, Ashwood P, Braunschweig D, Cabanlit M, Van de Water J, Amaral DG. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav Immun. 2008;22:806–816. [PMC free article] [PubMed]
  • McAllister DL, Kaplan BJ, Edworthy SM, Martin L, Crawford SG, Ramsey-Goldman R, Manzi S, Fries JF, Sibley J. The influence of systemic lupus erythematosus on fetal development: cognitive, behavioral, and health trends. J Int Neuropsychol Soc. 1997;3:370–376. [PubMed]
  • McCarthy N, Giesecke J. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol. 2001;153:610–614. [PubMed]
  • Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurology. 2009a;8:475–490. [PMC free article] [PubMed]
  • Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. The Lancet Neurology. 2009b;8:475–490. [PMC free article] [PubMed]
  • Missias AC, Mudd J, Cunningham JM, Steinbach JH, Merlie JP, Sanes JR. Deficient development and maintenance of postsynaptic specializations in mutant mice lacking an ‘adult’ acetylcholine receptor subunit. Development (Cambridge, England) 1997;124:5075–5086. [PubMed]
  • Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell. 1999;98:427–436. [PubMed]
  • Molenaar PC. A relative weak leg muscle in the rolling Nagoya mouse as a model for Lambert-Eaton myasthenic syndrome. Journal of Neuroimmunology. 2008;201-202:166–171. [PubMed]
  • Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 1994;12:529–540. [PubMed]
  • Motomura M, Hamasaki S, Nakane S, Fukuda T, Nakao YK. Apheresis treatment in Lambert-Eaton myasthenic syndrome. Therapeutic Apheresis: Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis. 2000;4:287–290. [PubMed]
  • Murphy KM, Beston BR, Boley PM, Jones DG. Development of human visual cortex: a balance between excitatory and inhibitory plasticity mechanisms. Dev Psychobiol. 2005;46:209–221. [PubMed]
  • Nabeshima T, Mouri A, Murai R, Noda Y. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine. Ann N Y Acad Sci. 2006;1086:160–168. [PubMed]
  • Nagel A, Engel AG, Lang B, Newsom-Davis J, Fukuoka T. Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation. Ann Neurol. 1988a;24:552–558. [PubMed]
  • Nakazawa K, McHugh TJ, Wilson MA, Tonegawa S. NMDA receptors, place cells and hippocampal spatial memory. Nat Rev Neurosci. 2004;5:361–372. [PubMed]
  • Neuwelt E, Barnett P, Hellstrom I, Hellstrom K, Beaumier P, McCormick C, Weigel R. Delivery of melanoma-associated immunoglobulin monoclonal-antibody and Fab framgents to normal brain utilizing osmotic blood-brain-barrier disruption. Cancer Res. 1988;48:4725–4729. [PubMed]
  • Niehusmann P, Dalmau J, Rudlowski C, Vincent A, Elger CE, Rossi JE, Bien CG. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Archives of Neurology. 2009;66:458–464. [PubMed]
  • Nishikawa T, Tanii Y, Umino A, Hashimoto A, Hata N, Takashima M, Shirayama Y, Takahashi K. Phencyclidine, NMDA receptor and schizophrenia. Yakubutsu Seishin Kodo. 1991;11:65–69. [PubMed]
  • Noga JT, Wang H. Further postmortem autoradiographic studies of AMPA receptor binding in schizophrenia. Synapse. 2002;45:250–258. [PubMed]
  • Oguro K, Oguro N, Kojima T, Grooms SY, Calderone A, Zheng X, Bennett MVL, Zukin RS. Knockdown of AMPA receptor GluR2 expression causes delayed neurodegeneration and increases damage by sublethal ischemia in hippocampal CA1 and CA3 neurons. J Neurosci. 1999;19:9218–9227. [PubMed]
  • Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 1999;33:523–533. [PubMed]
  • Oomes PG, Jacobs BC, Hazenberg MPH, Banffer JRJ, Vandermeche FGA. Anti-GM(1) IgG antibodies and campylobacter bacteria in Guillain-Barre-syndrome - evidence of molecular mimicry. Ann Neurol. 1995;38:170–175. [PubMed]
  • Palmer CL, Cotton L, Henley JM. The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol Rev. 2005;57:253–277. [PMC free article] [PubMed]
  • Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Current Opinion in Pharmacology. 2007;7:39–47. [PubMed]
  • Peers C, Johnston I, Lang B, Wray D. Cross-linking of presynaptic calcium channels: a mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction. Neurosci Lett. 1993a;153:45–48. [PubMed]
  • Peers C, Johnston I, Lang B, Wray D. Cross-linking of presynaptic calcium channels: a mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction. Neuroscience Letters. 1993b;153:45–48. [PubMed]
  • Phillips LH. The Epidemiology of Myasthenia Gravis. Annals of the New York Academy of Sciences. 2003;998:407–412. [PubMed]
  • Pinto A, Gillard S, Moss F, Whyte K, Brust P, Williams M, Stauderman K, Harpold M, Lang B, Newsom-Davis J, Bleakman D, Lodge D, Boot J. Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci USA. 1998;95:8328–8333. [PubMed]
  • Pinto A, Iwasa K, Newland C, Newsom-Davis J, Lang B. The action of Lambert-Eaton myasthenic syndrome immunoglobulin G on cloned human voltage-gated calcium channels. Muscle & Nerve. 2002;25:715–724. [PubMed]
  • Plomp JJ, Van Kempen GT, De Baets MB, Graus YM, Kuks JB, Molenaar PC. Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann Neurol. 1995;37:627–636. [PubMed]
  • Polizzi A, Huson S, Vincent A. Teratogen update: Maternal myasthenia gravis as a cause of congenital arthrogryposis. Teratology. 2000;62:332–341. [PubMed]
  • Posner JB, Dalmau JO. Paraneoplastic syndromes of the nervous system. Clin Chem Lab Med. 2000;38:117–122. [PubMed]
  • Pourmand R. Lambert-eaton myasthenic syndrome. Front Neurol Neurosci. 2009;26:120–125. [PubMed]
  • Prange O, Wong TP, Gerrow K, Wang YT, El-Husseini A. A balance between excitatory and inhibitory synapses is controlled by PSD-95 and neuroligin. Proc Natl Acad Sci U S A. 2004;101:13915–13920. [PubMed]
  • Prosser HM, Gill CH, Hirst WD, Grau E, Robbins M, Calver A, Soffin EM, Farmer CE, Lanneau C, Gray J, Schenck E, Warmerdam BS, Clapham C, Reavill C, Rogers DC, Stean T, Upton N, Humphreys K, Randall A, Geppert M, Davies CH, Pangalos MN. Epileptogenesis and enhanced prepulse inhibition in GABAB1-deficient mice. Molecular and Cellular Neuroscience. 2001;17:1059–1070. [PubMed]
  • Rabchevsky AG, Degos JD, Dreyfus PA. Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood-brain barrier without inducing reactive gliosis. Brain Res. 1999;832:84–96. [PubMed]
  • Rassendren FA, Lory P, Pin JP, Nargeot J. Zinc has opposite effects on NMDA and Non-NMDA receptors expressed in xenopus oocytes. Neuron. 1990;4:733–740. [PubMed]
  • Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med. 1995;333:1374–1379. [PubMed]
  • Reisel D, Bannerman DM, Schmitt WB, Deacon RMJ, Flint J, Borchardt T, Seeburg PH, Rawlins JNP. Spatial memory dissociations in mice lacking GluR1. Nat Neurosci. 2002;5:868–873. [PubMed]
  • Rho JM, Szot P, Tempel BL, Schwartzkroin PA. Developmental seizure susceptibility of kv1.1 potassium channel knockout mice. Developmental Neuroscience. 1999;21:320–327. [PubMed]
  • Riemersma S, Vincent A, Beeson D, Newland C, Hawke S, Vernet-der Garabedian B, Eymard B, Newsom-Davis J. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J Clin Invest. 1996;98:2358–2363. [PMC free article] [PubMed]
  • Rogers SW, Andrews PI, Gahring LC, Whisenand T, Cauley K, Crain B, Hughes TE, Heinemann SF, McNamara JO. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science. 1994;265:648–651. [PubMed]
  • Ross G, Sammaritano L, Nass R, Lockshin M. Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med. 2003;157:397–402. [PubMed]
  • Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle & Nerve. 2000;23:1800–1818. [PubMed]
  • Sahashi K, Engel AG, Lambert EH, Howard FM. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol. 1980;39:160–172. [PubMed]
  • Sanderson DJ, Gray A, Simon A, Taylor AM, Deacon RMJ, Seeburg PH, Sprengel R, Good MA, Rawlins JNP, Bannerman DM. Deletion of glutamate receptor-A (GluR-A) AMPA receptor subunits impairs one-trial spatial memory. Behavioral Neuroscience. 2007;121:559–569. [PubMed]
  • Sansing LH, Tuzun E, Ko MW, Baccon J, Lynch DR, Dalmau J. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol. 2007;3:291–296. [PMC free article] [PubMed]
  • Schmitt A, Fendt M, Zink M, Ebert U, Starke M, Berthold M, Herb A, Petroianu G, Falkai P, Henn FA. Altered NMDA receptor expression and behavior following postnatal hypoxia: potential relevance to schizophrenia. J Neural Transm. 2007;114:239–248. [PubMed]
  • Schuler V, Lüscher C, Blanchet C, Klix N, Sansig G, Klebs K, Schmutz M, Heid J, Gentry C, Urban L, Fox A, Spooren W, Jaton AL, Vigouret JM, Pozza M, Kelly PH, Mosbacher J, Froestl W, Käslin E, Korn R, Bischoff S, Kaupmann K, van der Putten H, Bettler B. Epilepsy, Hyperalgesia, Impaired Memory, and Loss of pre- and postsynaptic GABAB responses in mice lacking GABAB(1) Neuron. 2001;31:47–58. [PubMed]
  • Shepherd JD, Huganir RL. The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu Rev Cell Dev Biol. 2007;23:613–643. [PubMed]
  • Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ, Plomp JJ, van Kempen GT, Chauplannaz G, Wintzen AR. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Annals of Neurology. 1995;38:714–722. [PubMed]
  • Shim SS, Hammonds MD, Kee BS. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci. 2008;258:16–27. [PubMed]
  • Smitt PAES, Polman SKL, de Beukelaar JWK, Enting RH, van den Bent MJ, Bromberg JE, Kros JM, Hooijkaas H. Three patients with a paraneoplastic neurological syndrome: the significance of paraneoplastic antibodies. Nederlands Tijdschrift Voor Geneeskunde. 2007;151:874–880. [PubMed]
  • Sobolevsky AI, Rosconi MP, Gouaux E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature. 2009;462:745–756. [PMC free article] [PubMed]
  • Sprengel R. Role of AMPA receptors in synaptic plasticity. Cell Tissue Res. 2006;326:447–455. [PubMed]
  • Stahl SM. Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectr. 2007a;12:265–268. [PubMed]
  • Stahl SM. The genetics of schizophrenia converge upon the NMDA glutamate receptor. CNS Spectr. 2007b;12:583–588. [PubMed]
  • Standaert DG, Testa CM, Young AB, Penney JB., Jr Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J Comp Neurol. 1994;343:1–16. [PubMed]
  • Stein-Wexler R, Wootton-Gorges SL, Greco CM, Brunberg JA. Paraneoplastic limbic encephalitis in a teenage girl with an immature ovarian teratoma. Pediatr Radiol. 2005;35:694–697. [PubMed]
  • Sutton M, Ito H, Cressy P, Kempf C, Woo J. Miniature neurotransmission stabilizes synaptic function via tonic suppression of … Cell 2006 [PubMed]
  • Takamori M, Maruta T, Komai K. Lambert-Eaton myasthenic syndrome as an autoimmune calcium-channelopathy. Neuroscience Research. 2000;36:183–191. [PubMed]
  • Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology. 2004;62:1177–1182. [PubMed]
  • Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematology/Oncology Clinics of North America. 2008;22:509–526. [PubMed]
  • Toyka KV, Brachman DB, Pestronk A, Kao I. Myasthenia gravis: passive transfer from man to mouse. Science. 1975;190:397–399. [PubMed]
  • Tsien JZ, Huerta PT, Tonegawa S. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell. 1996;87:1327–1338. [PubMed]
  • Turrigiano GG, Leslie KR, Desai NS, Rutherford LC, Nelson SB. Activity-dependent scaling of quantal amplitude in neocortical neurons. Nature. 1998;391:892–896. [PubMed]
  • Tüzün E, Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment. The Neurologist. 2007;13:261–271. [PubMed]
  • Vernino S, Adamski J, Kryzer TJ, Fealey RD, Lennon VA. Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology. 1998;50:1806–1813. [PubMed]
  • Vernino S, Ermilov LG, Sha L, Szurszewski JH, Low PA, Lennon VA. Passive transfer of autoimmune autonomic neuropathy to mice. The Journal of Neuroscience. 2004;24:7037–7042. [PMC free article] [PubMed]
  • Vernino S, Lindstrom J, Hopkins S, Wang Z, Low PA. Characterization of ganglionic acetylcholine receptor autoantibodies. Journal of Neuroimmunology. 2008;197:63–69. [PMC free article] [PubMed]
  • Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. The New England Journal of Medicine. 2000;343:847–855. [PubMed]
  • Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, Clover L, Parkinson A, Bien CG, Omer S, Lang B, Rossor MN, Palace J. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004;127:701–712. [PubMed]
  • Vincent A, Newland C, Brueton L, Beeson D, Riemersma S, Huson SM, Newsom-Davis J. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet. 1995;346:24–25. [PubMed]
  • Wang Z, Low PA, Jordan J, Freeman R, Gibbons CH, Schroeder C, Sandroni P, Vernino S. Autoimmune autonomic ganglionopathy: IgG effects on ganglionic acetylcholine receptor current. Neurology. 2007;68:1917–1921. [PMC free article] [PubMed]
  • Waters P, Jarius S, Littleton E, Leite MI, Jacob S, Gray B, Geraldes R, Vale T, Jacob A, Palace J, Maxwell S, Beeson D, Vincent A. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol. 2008;65:913–919. [PubMed]
  • Waxman EA, Lynch DR. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist. 2005;11:37–49. [PubMed]
  • Whitney KD, Andrews PI, McNamara JO. Immunoglobulin G and complement immunoreactivity in the cerebral cortex of patients with Rasmussen's encephalitis. Neurology. 1999;53:699–708. [PubMed]
  • Wiedholz LM, Owens WA, Horton RE, Feyder M, Karlsson RM, Hefner K, Sprengel R, Celikel T, Daws LC, Holmes A. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and ‘schizophrenia-related’ behaviors. Mol Psychiatry. 2008;13:631–640. [PubMed]
  • Wilson S, Vincent A, Newsom-Davis J. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis. J Neurol Neurosurg Psychiatr. 1983;46:383–387. [PMC free article] [PubMed]
  • Xaio H, Banks WA, Niehoff ML, Morley JE. Effect of LPS on the permeability of the blood-brain barrier to insulin. Brain Res. 2001;896:36–42. [PubMed]
  • Xu W, Gelber S, Orr-Urtreger A, Armstrong D, Lewis RA, Ou CN, Patrick J, Role L, De Biasi M, Beaudet AL. Megacystis, mydriasis, and ion channel defect in mice lacking the alpha3 neuronal nicotinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:5746–5751. [PubMed]
  • Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, Taguchi K, Miyatake T, Furukawa K, Kobata T, Yamada M. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci USA. 2004;101:11404–11409. [PubMed]
  • Zamanillo D, Sprengel R, Hvalby Oslash, ivind Jensen V, Burnashev N, Rozov A, Kaiser KM, nbsp M ouml ster HJ, Borchardt T, Worley P, uuml bke J, Frotscher M, Kelly PH, Sommer B, Andersen P, Seeburg PH, Sakmann B. Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning. Science. 1999;284:1805–1811. [PubMed]
  • Zavitsanou K, Nguyen V, Newell K, Ballantyne P, Huang XF. Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: implications for schizophrenia. J Chem Neuroanat. 2008;36:71–76. [PubMed]